Strata Skin Sciences files Form 25 to delist common stock

Strata Skin Sciences, Inc. filed a Form 25 notifying the removal of its Common Stock, $0.001 par value from The Nasdaq Stock Market LLC.

Rhea-AI Filing Summary

Strata Skin Sciences, Inc. filed a Form 25 notifying the removal of its Common Stock, $0.001 par value from The Nasdaq Stock Market LLC. The filing states the Exchange and the issuer have each complied with the procedures set forth in 17 CFR 240.12d2-2. The notice is dated February 19, 2026 and bears a signature block from John Gillings, Chief Accounting Officer.

Insights

Corporate Secretary / Listing Compliance Expert

Form 25 notifies Nasdaq delisting with procedural compliance cited.

The filing lists the class as Common Stock, $0.001 par value and cites compliance with 17 CFR 240.12d2-2 subdivisions (a)(1)-(4), (b) and (c), indicating both the Exchange and the issuer followed the regulatory steps for removal.

The notice is dated February 19, 2026. Timing, market treatment, and next procedural steps are not detailed in the excerpt; subsequent filings or exchange notices will clarify effective delisting date and trading consequences.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Strata Skin Sciences (SSKN) file Form 25?

The company filed Form 25 to notify the removal of its Common Stock, $0.001 par value from Nasdaq. The filing cites compliance with 17 CFR 240.12d2-2 procedural provisions for delisting.

When was the Form 25 for SSKN signed?

The notice is dated February 19, 2026. The signature block shows John Gillings, Chief Accounting Officer, signed the form on that date.

Does the filing state Nasdaq followed proper procedures?

Yes; the filing states the Exchange complied with its rules under 17 CFR 240.12d2-2(b), indicating the Exchange followed the listed procedural requirements for striking the class from listing.

Does the filing state the issuer complied with Nasdaq rules?

Yes; the filing includes a statement that the issuer complied with Exchange rules and 17 CFR 240.12d2-2(c) governing voluntary withdrawal of listing and registration.

What class of securities is being removed from Nasdaq?

The filing identifies the affected class as Common Stock, $0.001 par value per share for Strata Skin Sciences, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 04:00 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR

REGISTRATION UNDER SECTION 12(b) OF THE

SECURITIES EXCHANGE ACT OF 1934

Commission File No. 000-51481

STRATA Skin Sciences, Inc.

The Nasdaq Stock Market LLC

(Exact name of registrant as specified in its charter, and name of Exchange where security is listed and/or registered)

5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania 19044; (215) 619-3200

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Common Stock, $0.001 par value per share

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

☐	17 CFR 240.12d2-2(a)(1)
☐	17 CFR 240.12d2-2(a)(2)
☐	17 CFR 240.12d2-2(a)(3)
☐	17 CFR 240.12d2-2(a)(4)
☐	Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.
☒	Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Minerva Surgical, Inc. certifies that is has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

Date: February 19, 2026	/s/ John Gillings
	John Gillings
	Chief Accounting Officer